BiotechTube

Doxycycline 50Mg Tablet

Phase 2Completed
1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Skin Toxicity

Conditions

Skin Toxicity

Trial Timeline

May 10, 2018 → Apr 6, 2020

NCT ID
NCT03448731

About Doxycycline 50Mg Tablet

Doxycycline 50Mg Tablet is a phase 2 stage product being developed by Amgen for Skin Toxicity. The current trial status is completed. This product is registered under clinical trial identifier NCT03448731. Target conditions include Skin Toxicity.

What happened to similar drugs?

16 of 20 similar drugs in Skin Toxicity were approved

Approved (16) Terminated (4) Active (4)
✅Vancomycin + Daptomycin + Semi-Synthetic PenicillinMerckApproved
✅Daptomycin + Standard of Care (SOC)MerckApproved
✅Daptomycin + VancomycinMerckApproved
✅Daptomycin + VancomycinMerckApproved
✅DaptomycinNovartisApproved
✅Tigecycline + ampicillin-sulbactamPfizerApproved
✅linezolid + vancomycinPfizerApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03448731Phase 2Completed

Competing Products

20 competing products in Skin Toxicity

See all competitors
ProductCompanyStageHype Score
[203Pb]VMT01 + [212Pb]VMT01 + NivolumabPerspective TherapeuticsPhase 1/2
33
[203Pb]VMT01 + [68Ga]VMT02Perspective TherapeuticsPhase 1
23
Mupirocin Calcium Cream, 2% + Bactroban® Cream + Cream vehicle of test productSun PharmaceuticalPhase 1
29
LY3041658 + PlaceboEli LillyPhase 1
29
DSP-9632P 27.5 mg + DSP-9632P 82.5 mg + Placebo + DSP-9632P 55.0 mg + Levodopa formulationSumitomo PharmaPhase 1
29
levofloxacinJohnson & JohnsonPhase 2/3
38
Moisturizer A, F#9155-005Johnson & JohnsonPre-clinical
26
levofloxacinJohnson & JohnsonPhase 3
40
CeftobiproleJohnson & JohnsonPhase 1
29
Natural Killer Cell Therapy + Universal Donor Expanded TGF-beta-imprinted NK CellsJohnson & JohnsonPhase 1
36
LevofloxacinJohnson & JohnsonPhase 3
40
CeftobiproleJohnson & JohnsonPhase 1
29
Levodopa-carbidopa intestinal gelAbbViePhase 3
40
IressaAstraZenecaPhase 2
35
Daptomycin + VancomycinAstraZenecaPhase 3
40
SarizotanMerckPre-clinical
18
Pembrolizumab + EDP1503MerckPhase 2
27
testosterone gel + Comparator: placeboMerckPhase 1
29
LNS8801 + Pembrolizumab + Chemotherapy (dacarbazine or temozolomide) + Immunotherapy (Pembrolizumab) + Immunotherapy (nivolumab and relatlimab) + Immunotherapy (ipilimumab and nivolumab)MerckPhase 2/3
45
Vancomycin + Daptomycin + Semi-Synthetic PenicillinMerckApproved
35